ReviewJournal of reproductive immunology2009
Chlamydial protease-like activity factor--insights into immunity and vaccine development.
Review in Journal of reproductive immunology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 23 citations in OpenAlex.
- Review
- Intranasal immunization with recombinant chlamydial protease-like activity factor attenuates atherosclerotic pathology following Chlamydia pneumoniae infection in mice.Immunology and cell biology · 2019Article
- Chlamydial protease-like activity factor mediated protection against C. trachomatis in guinea pigs.Immunology and cell biology · 2017Article
- Antigen specific immune response in Chlamydia muridarum genital infection is dependent on murine microRNAs-155 and -182.Oncotarget · 2016Article
- In vivo whole animal body imaging reveals colonization of Chlamydia muridarum to the lower genital tract at early stages of infection.Molecular imaging and biology · 2014Article
- Reassessing the role of the secreted protease CPAF in Chlamydia trachomatis infection through genetic approaches.Pathogens and disease · 2014Article
- A path forward for the chlamydial virulence factor CPAF.Microbes and infection · 2013Review
- Intranasal vaccination with Chlamydia pneumoniae induces cross-species immunity against genital Chlamydia muridarum challenge in mice.PloS one · 2013Article
- Immunogenic recombinant Burkholderia pseudomallei MprA serine protease elicits protective immunity in mice.Frontiers in cellular and infection microbiology · 2012Article
- Chlamydia psittaci genetic variants differ in virulence by modulation of host immunity.The Journal of infectious diseases · 2011Article
- Vaccination against Chlamydia genital infection utilizing the murine C. muridarum model.Infection and immunity · 2011Review
- Immunity and vaccines against sexually transmitted Chlamydia trachomatis infection.Current opinion in infectious diseases · 2011Review
- Immunization with a combination of integral chlamydial antigens and a defined secreted protein induces robust immunity against genital chlamydial challenge.Infection and immunity · 2010Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
Chlamydia trachomatis is a Gram-negative obligate intracellular pathogen that remains the leading cause of bacterial sexually transmitted disease worldwide, despite the availability of efficacious antimicrobial therapy. Given that chlamydial infections cause severe pathological sequelae in the upper genital tract, a licensed vaccine to prevent infection and disease would be an ideal solution. Chlamydial protease-like activity factor (CPAF) is a protein secreted in considerable amounts into the cytosol of infected cells and released into the extracellular milieu upon cellular lysis, which therefore is accessible to the host immune system. This is further substantiated by the observation that CPAF is immunodominant among other antigens in Chlamydia sero-positive humans. The efficacy of vaccination with CPAF against genital chlamydial challenge has been evaluated extensively in the murine model. This review will discuss important insights into the potential of CPAF as a component of an anti-chlamydial vaccine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.